Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia
Patient Screening and Enrollment Underway With Results Anticipated Before Year-End
First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System
Risperidone is one of the most widely prescribed medications used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable antipsychotic market was approximately
If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing.
The DosePro system is a first-in-class, easy-to-use drug delivery system that includes a pre-filled, single dose of sterile liquid drug, and is administered subcutaneously, without a needle. The platform is currently used by
For additional information, please visit www.zogenix.com.
Forward Looking Statements
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and
SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of
SABER® is a trademark of
CONTACT: Investor Contact
Zack Kubow| The Ruth Group646.536.7020 | firstname.lastname@example.org Media Contact Victoria Aguiar| The Ruth Group646.536.7013 | email@example.com